7 patients in the acute and 51 patients in the chronic stages of opisthorchiasis were treated with azynoks in daily dose 60 mg per kilo. The radical cure was achieved in 95.8 +/- 0.4% of cases. The wild side effects (headache, vertigo, nausea, fatigue) were registered in 51.7 +/- 9.1% of the cases, predominantly during the first hours of the treatment. The biochemical and immunological changes during the first 2 weeks after azynoks administration were analogues to those seen after biltricide and chloxyl (hexaparaxylol) treatment.

Download full-text PDF

Source

Publication Analysis

Top Keywords

[the trial
4
trial treating
4
treating opisthorchiasis
4
opisthorchiasis soviet
4
soviet preparation
4
preparation azinoks]
4
azinoks] patients
4
patients acute
4
acute patients
4
patients chronic
4

Similar Publications

Background: The results of many large randomized clinical trials (RCTs) have transformed clinical practice in gastroesophageal reflux disease (GERD) and esophageal hiatal hernia (HH). However, research waste (i.e.

View Article and Find Full Text PDF

Background: Crohn's disease (CD) is a chronic, recurrent gastrointestinal disorder characterized by a complex etiology. Among its perianal complications, anal fistulas represent a challenging comorbidity. With the increase of surgical options, a comprehensive bibliometric analysis was deemed necessary to consolidate the vast array of research in this field.

View Article and Find Full Text PDF

Importance: Pediatric peripheral intravenous catheter (PIVC) insertion can be difficult and time-consuming, frequently requiring multiple insertion attempts and often resulting in increased anxiety, distress, and treatment avoidance among children and their families. Ultrasound-guided PIVC insertion is a superior alternative to standard technique (palpation and visualization) in high-risk patients.

Objective: To compare first-time insertion success of PIVCs inserted with ultrasound guidance compared with standard technique (palpation and visualization) across all risk categories in the general pediatric hospital population.

View Article and Find Full Text PDF

Importance: In the Atrial Cardiopathy and Antithrombotic Drugs in Prevention After Cryptogenic Stroke (ARCADIA) randomized clinical trial, anticoagulation did not prevent recurrent stroke among patients with a recent cryptogenic stroke and atrial cardiopathy. It is unknown whether anticoagulation prevents covert infarcts in this population.

Objective: To test the use of apixaban vs aspirin for prevention of nonlacunar covert infarcts after cryptogenic stroke in patients with atrial cardiopathy.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!